Complete Surgical Metastasectomy in Metastatic Renal Cell Carcinoma
Complete surgical metastasectomy may more than double life expectancy for patients with late-stage kidney cancer, according to new research published by Harris B. Zaid, MD, of the Department of Urology, Mayo Clinic and Medical School, Rochester, Minnesota, and colleagues, in The Journal of Urology. Results from their meta-analysis suggest consideration should be given to performing complete surgical metastasectomy in patients with metastatic renal cell carcinoma when feasible, as they observed a “clinically meaningful difference in survival” between patients who underwent metastasectomy and those who did not.
“The research found patients who had surgery to remove metastases were about half as likely to have died from their metastatic disease at every point in time after diagnosis,” said Bradley Leibovich, MD, a urologist at Mayo Clinic and senior author of the study article.
The researchers analyzed 8 previous studies on a total of 2267 patients (958 with complete surgical metastasectomy and 1309 with incomplete surgical metastasectomy). Median overall survival ranged from 3 to 12 years for those with complete surgical metastasectomy, versus 8 months to about 2 years for those with incomplete surgical metastasectomy.
In a future study, the team will evaluate the interaction of surgery and drugs to determine whether the combination further increases survival.